LCMD-L302P-UCL01C2
UCLi006-A
General
Cell Line |
|
| hPSCreg name | UCLi006-A |
| Cite as: | UCLi006-A (RRID:CVCL_VF11) |
| Alternative name(s) |
LCMD-L302P-UCL01C2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
FAMRCi007-A (LMNA #23) Donor's gene variants: LMNA Donor diseases: atrioventricular block Emery-Dreifuss Muscular Dystrophy Paroxysmal atrial fibrillation FAMRCi007-B (LMNA #19) Donor's gene variants: LMNA Donor diseases: atrioventricular block Emery-Dreifuss Muscular Dystrophy Paroxysmal atrial fibrillation PUMCHi001-A-1 (IPS34-R-17) Donor's gene variants: LMNA Donor diseases: familial partial lipodystrophy type 2 FAMRCi005-A (LMNA B4) Donor's gene variants: LMNA Donor diseases: myopathy atrioventricular block Paroxysmal ventricular tachycardia FAMRCi005-B (LMNA B5) Donor's gene variants: LMNA Donor diseases: myopathy atrioventricular block Paroxysmal ventricular tachycardia FAMRCi006-A (LMNA T3) Donor's gene variants: LMNA Donor diseases: Emery-Dreifuss Muscular Dystrophy Dilated Cardiomyopathy FAMRCi006-B (LMNA T4) Donor's gene variants: LMNA Donor diseases: Emery-Dreifuss Muscular Dystrophy Dilated Cardiomyopathy UNEWi026-A (SF116 clone 1) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UNEWi026-B (SF116 clone 2) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UNEWi026-C (SF116 clone K) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UKBi003-A (iLB-MJD1-32m-r9, LB-32-r9) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease UKBi008-A (iLB-MJD4-34m-r1, LB-34-1) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease UKBi007-A (LB-33-5, iLB-MJD3-33f-r5) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease |
| Last update | 18th October 2019 |
| User feedback | |
Provider |
|
| Generator | University College London (UCL) |
| Distributors | |
| Derivation country | United Kingdom |
External Databases |
|
| BioSamples | SAMEA104130970 |
| Cellosaurus | CVCL_VF11 |
| Wikidata | Q54989674 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA104130971 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | Jean-Marie.CUISSET@CHRU-LILLE.FR |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | Use in research for muscular dystrophies |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | |
| Approval number | |
| Do you have obligations to third parties in regard to the use of the cell line? | Yes |
| Please describe: | Use in research for muscular dystrophies |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
Any skin fibroblast that is part of some dermis.
|
| Source cell origin |
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Lentivirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
No |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
Immunostaining, RT-PCR
|
| Vector map | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Vitronectin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| Medium |
TeSR™ E8™
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| SOX2 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| Alkaline Phosphatase |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.